We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $269M
1-Year Est. Return 103.38%
This Fund
S&P 500
This Quarter Est. Return
+42.01%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$293M
AUM Growth
+$81.7M
Cap. Flow
+$12.9M
Cap. Flow %
4.42%
Top 10 Hldgs %
60.12%
Holding
48
New
11
Increased
16
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
EYPT icon
EyePoint Inc
EYPT
+$7.48M
2
GUTS icon
Fractyl Health
GUTS
+$6.49M
3
MDWD icon
MediWound
MDWD
+$6.31M
4
HELP
Cybin Inc
HELP
+$4.88M
5
ATYR
aTyr Pharma
ATYR
+$4.71M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$9.79M
2
URGN icon
UroGen Pharma
URGN
+$7.43M
3
REPL icon
Replimune Group
REPL
+$5.75M
4
PHVS icon
Pharvaris
PHVS
+$3.94M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$3.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.72%
2 Miscellaneous 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$567M
$33M 11.28%
3,300,389
– –
CYTK icon
2
Cytokinetics
CYTK
$10B
$22M 7.51%
400,000
– –
FENC icon
3
Fennec Pharmaceuticals
FENC
$430M
$19.4M 6.64%
2,076,840
+31,196
+2% +$270K
VSTM icon
4
Verastem
VSTM
$654M
$17M 5.82%
1,929,563
-114,000
-6% -$848K
RZLT icon
5
Rezolute
RZLT
$445M
$17M 5.81%
1,807,202
+65,991
+4% +$439K
XERS icon
6
Xeris Biopharma Holdings
XERS
$1.55B
$14.6M 5%
1,795,766
-359,828
-17% -$2.39M
SVRA icon
7
Savara
SVRA
$1.08B
$14.3M 4.88%
4,000,000
+1,345,056
+51% +$3.98M
MDWD icon
8
MediWound
MDWD
$163M
$13.5M 4.61%
749,054
+341,993
+84% +$6.31M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.61B
$12.9M 4.43%
600,000
-100,000
-14% -$1.8M
CGON icon
10
CG Oncology
CGON
$6.59B
$12.1M 4.13%
300,000
+107,026
+55% +$3.11M
VRNA
11
DELISTED
Verona Pharma
VRNA
$10.7M 3.65%
100,000
– –
IDYA icon
12
IDEAYA Biosciences
IDYA
$3.87B
$9.52M 3.26%
350,000
-161,132
-32% -$3.9M
NSPR icon
13
InspireMD
NSPR
$39.8M
$9.41M 3.22%
3,905,743
+1,616,644
+71% +$3.92M
EYPT icon
14
EyePoint Inc
EYPT
$386M
$9.26M 3.16%
+650,000
New +$7.48M
DFTX
15
Definium Therapeutics
DFTX
$5.51B
$8.84M 3.02%
750,000
+330,000
+79% +$3.08M
HELP
16
Cybin Inc
HELP
$890M
$8.84M 3.02%
1,500,000
+689,082
+85% +$4.88M
GUTS icon
17
Fractyl Health
GUTS
$105M
$7.95M 2.72%
+5,000,000
New +$6.49M
ATYR
18
aTyr Pharma
ATYR
$53M
$7.56M 2.59%
+1,039,080
New +$4.71M
QURE icon
19
uniQure
QURE
$3.38B
$7.3M 2.49%
+125,000
New +$2.27M
XFOR icon
20
X4 Pharmaceuticals
XFOR
$401M
$5.28M 1.81%
+1,544,607
New +$3.98M
OCUL icon
21
Ocular Therapeutix
OCUL
$2.28B
$4.68M 1.6%
400,000
-818,700
-67% -$9.79M
ATYR
22
PUT
aTyr Pharma
ATYR
$53M
$4.47M 1.53%
1,570,200
+1,347,200
+604% +$6.1M
TLPH icon
23
Talphera
TLPH
$62.3M
$3.92M 1.34%
4,385,757
+2,381,818
+119% +$1.38M
PROF
24
Profound Medical
PROF
$250M
$3.38M 1.16%
692,185
– –
MYO icon
25
Myomo
MYO
$63.4M
$3.38M 1.16%
3,790,788
+195,000
+5% +$284K
1
2

Similar funds

GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
AFO
Allie Family Office Miami, Florida $269M AUM 20.2% 1-Year Est. Return
TW
Titan Wealth St Peter Port $269M AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
ZEP
Zeno Equity Partners London, United Kingdom $269M AUM 6.35% 1-Year Est. Return
LBW
Landesbank Baden-Wuerttemberg Stuttgart Baden-Wuerttemberg, Germany $269M AUM
VP
Verisail Partners Chamblee, Georgia $270M AUM 16.03% 1-Year Est. Return
5W
5T Wealth Napa, California $269M AUM 17.81% 1-Year Est. Return

Rosalind Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Rosalind Advisors held 48 positions worth $293M, up 39% from $211M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Rosalind Advisors deployed $12.9M of net new capital in Q3 2025, opening 11 new positions and adding to 16 existing holdings. Its largest new stake was EyePoint Inc: 650,000 shares worth $9.26M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $9.79M trimmed.

  • Rosalind Advisors's largest Q3 2025 buy was EyePoint Inc: 650,000 shares worth $9.26M.
  • Rosalind Advisors added most to MediWound in Q3 2025, an estimated $6.31M increase.
  • Rosalind Advisors's biggest Q3 2025 reduction was Ocular Therapeutix, cutting an estimated $9.79M.
  • Rosalind Advisors fully exited UroGen Pharma in Q3 2025, selling an estimated $7.43M.
  • Rosalind Advisors's ten largest holdings make up 60% of its $293M portfolio in Q3 2025.
  • Rosalind Advisors opened 11 new positions and closed 9 in Q3 2025.
  • Rosalind Advisors's portfolio value rose 39% quarter-over-quarter to $293M.

Based on Rosalind Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.